Cyteir Therapeutics, Inc. (CYT)
| Market Cap | 199.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.67M |
| Shares Out | 35.37M |
| EPS (ttm) | -3.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,735 |
| Open | 6.06 |
| Previous Close | 6.06 |
| Day's Range | 5.50 - 6.22 |
| 52-Week Range | 5.40 - 23.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CYT
Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver ...
Financial Performance
Financial StatementsNews
Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...
Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, tod...
Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...
Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...
Cyteir Therapeutics Selected to Join Russell 2000® Index
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was...
Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...
Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...
Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...
Cyteir Therapeutics Announces Closing of Initial Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...
Cyteir Therapeutics Announces Pricing of Initial Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...